Noxopharm (ASX:NOX) Accumulated other comprehensive income (loss) : A$0.93 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Noxopharm's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was A$0.93 Mil.

Noxopharm's quarterly Accumulated other comprehensive income (loss) declined from Dec. 2022 (A$6.68 Mil) to Jun. 2023 (A$6.50 Mil) and declined from Jun. 2023 (A$6.50 Mil) to Dec. 2023 (A$0.93 Mil).

Noxopharm's annual Accumulated other comprehensive income (loss) declined from Jun. 2021 (A$8.49 Mil) to Jun. 2022 (A$8.29 Mil) and declined from Jun. 2022 (A$8.29 Mil) to Jun. 2023 (A$6.50 Mil).

Noxopharm Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Noxopharm's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Accumulated other comprehensive income (loss) Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

4.46

2.71

8.49

8.29

6.50

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial										7.65	8.29	6.68	6.50	0.93

Noxopharm Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Noxopharm Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Noxopharm's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (ASX:NOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

NOXOF:USA

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines